Abstract
Hepatitis C (HCV) is one of the major infectious diseases in the world. Injection drug users (PWID) is a population who is at higher risk of acquisition of HCV due to risky behaviors such as needle sharing, and they are considered as an important factor in the spread of the disease. World Health Organization (WHO) aims to eliminate hepatitis C disease by 2030 with the help of approval and dissemination of newly developed direct-acting antiviral treatment regimes. In this study, we evaluated the cost-effectiveness of hepatitis C treatment among injected drug users in Turkey to observe whether it is possible to reach WHO targets. Purpose of our model is to determine the infected population in the future, and we simulated the injected drug user population with a time horizon of 20 years. We developed five scenarios to represent different levels of treatment coverage. We included treatment regimens that are available in Turkey and that are reimbursed by the government health care insurance policies, which roughly covers over 90% of the Turkish population. Our model objective is (i) to predict the spread of HCV in the next 20 years, (ii) to determine the cost of new treatment regimens available to Turkish PWID population and (iii) to estimate the cost-effectiveness of these regimes. Our results indicate that HCV infected PWIDs could significantly decrease with treatment while the lowest total cost of treatment could be achieved with Viekirax Exviera and Mavyret. Also, it is possible to reach WHO targets by 2030 in Turkey if the treatment coverage increases.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alaei A, Alaei K, Waye K, Tracy M, Nalbandyan M, Mutlu E, Cetin MK (2017) Hepatitis C infection and other drug-related harms among inpatients who injected drugs in Turkey. J Viral Hepatitis 24:496–505. https://doi.org/10.1111/jvh.12662
Bağımlılık Yapıcı Maddeler ve Bağımlılık Ile Mücadele 2007 Yılı Ulusal Raporu (2007) http://www.emcdda.europa.eu/system/files/publications/942/NR2007Tureky_tr.pdf
Barut ÅžH (n.d.) Hepatit C Viroloji ve Epidemiyoloji. https://www.klimik.org.tr/wp-content/uploads/2016/01/Hepatit-C-viroloji-ve-epidemiyoloji-Åžener-Barut.pdf
Bayer College of Medicine (n.d.) Introduction to infectious diseases. https://www.bcm.edu/departments/molecular-virology-and-microbiology/emerging-infections-and-biodefense/introduction-to-infectious-diseases. Accessed 10 Mar 2019
Van Den Berg CHSB, Smit C, Bakker M, Geskus RB, Berkhout B, Jurriaans S, Coutinho RA, Wolthers KC, Prins M (2007) Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug users. Eur J Epidemiol. https://doi.org/10.1007/s10654-006-9089-7
Centers for Disease Control and Prevention (n.d.) What is the recommended management of a health care worker with occupational exposure to HCV? https://www.cdc.gov/hepatitis/hcv/hcvfaq.htm#Ref24
Chhatwal J, Kanwal F, Roberts MS, Dunn MA (2015) Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. Author Manuscrip 162(6):397–406. https://doi.org/10.1097/CCM.0b013e31823da96d.Hydrogen
Cipriano LE, Zaric GS, Holodniy M, Bendavid E, Owens DK, Brandeau ML (2012) Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users. PLoS ONE 7(9). https://doi.org/10.1371/journal.pone.0045176
Eastern Europe Population (n.d.) Worldometers. https://www.worldometers.info/population/europe/eastern-europe/. Accessed 10 Feb 2019
EMCDDA 2014 Ulusal Raporu (2013 Verileri) (2014) http://www.narkotik.pol.tr/TUBIM/Documents/TURKIYE UYUSTURUCU RAPORU 2014.pdf
Evren C, Tamar D, Ögel K (1996) Damar Yolu Ile Eroin Kullanımı ve İlişkili Bazı Davranış Biçimleri. http://www.ogelk.net/Dosyadepo/damar4.pdf
Grassly NC, Fraser C (2006) Seasonal infectious disease epidemiology. Proc R Soc B Biol Sci. https://doi.org/10.1098/rspb.2006.3604
Grebely J, Dore GJ (2011) Prevention of hepatitis C virus in injecting drug users: a narrow window of opportunity. J Infect Dis. https://doi.org/10.1093/infdis/jiq111
Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Russell E (1999) Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol 149(3):381. https://doi.org/10.1016/S0041-3879(38)80113-6
Hagan H, Pouget ER, Williams IT, Garfein RL, Strathdee SA, Hudson SM, Latka MH, Ouellet LJ (2010) Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. J Infect Dis 201(3):378–385. https://doi.org/10.1086/649783
He T, Li K, Roberts MS, Spaulding AC, Ayer T, Grefenstette JJ, Chhatwal J (2015) Prevention of hepatitis C by screening and treatment in U.S. prisons. Ann Intern Med. https://doi.org/10.7326/M15-0617
Hepatitis C and Health Care Personnel (n.d.) Centers for disease control and prevention. https://www.cdc.gov/hepatitis/hcv/hcvfaq.htm. Accessed 1 Jan 2019
Herkesin Başına Gelebilir. Hep C ve B… ve Biz (n.d.) Promethee
Hethcote HW (2000) The mathematics of infectious diseases. SIAM Rev 42(4):599–653
Irmak H, Yardım N, Keklik K, Temel F (n.d.) Türkiye Viral Hepatit Önleme ve Kontrol Programı 2018–2023. https://hsgm.saglik.gov.tr/depo/birimler/Bulasici-hastaliklar-. Accessed 1 Jan 2019
Kretzschmar M, Wallinga J (2010) Modern infectious disease epidemiology: concepts, methods, mathematical models, and public health. Krämer A, Gail M, Tsiatis A, Krickeberg K, Samet JM, Wong W, Kretzschmar M (eds). Springer, New York. https://doi.org/10.1016/s0035-9203(02)90396-2
Maor Y, Malnick SDH, Melzer E, Leshno M (2016) Treatment of chronic hepatitis C in the aged - does it impact life expectancy? A decision analysis. PLoS ONE. https://doi.org/10.1371/journal.pone.0157832
Mathers BM, Degenhardt L, Phillips B, Wiessing L, Hickman M, Strathdee SA, Wodak A et al (2008) Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. https://doi.org/10.1016/S0140-6736(08)61311-2
Ögel K, Tamar D, Evren C, Hızlan C (n.d.) Madde Kullanıcılarının Özellı̇klerı̇: Türkiye’de Çok Merkezli Bir Araştırma (İkinci Aşama)
Örmeci N, Malhan S, Balık İ, Ergör G, Razavi H, Robbins S (2017) Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey. Hep Intl 11:509–516. https://doi.org/10.1007/s12072-017-9820-3
Perz JF, Armstrong GL, Farrington LA, Hutin YJF, Bell BP (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. https://doi.org/10.1016/j.jhep.2006.05.013
Pfeil AM, Reich O, Guerra IM, Cure S, Negro F, Müllhaupt B, Lavanchy D, Schwenkglenks M (2015) Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C. PLoS ONE 10(5):1–20. https://doi.org/10.1371/journal.pone.0126984
Pınarcı M (2009) Bağımlılık Yapıcı Maddeler ve Bağımlılık Ile Mücadele 2009 Yılı Ulusal Raporu
Population: Central Asia (n.d.) Worldometers
Poynard T, Bedossa P, Opolon P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. https://doi.org/10.1016/S0140-6736(96)07642-8
Scott N, Iser DM, Thompson AJ, Doyle JS, Hellard ME (2016) Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia. J Gastroenterol Hepatol (Australia) 31(4):872–882. https://doi.org/10.1111/jgh.13223
Side S, Noorani SMd (2013) A SIR model for spread of dengue fever disease (simulation for South Sulawesi, Indonesia and Selangor, Malaysia). World J Model Simul 9(2):96–105. https://doi.org/10.2523/iptc-14328-ms
Stone L, Shulgin B, Agur Z (2000) Theoretical examination of the pulse vaccination policy in the SIR epidemic model. Math Comput Model 31:207–215. https://doi.org/10.1016/S0895-7177(00)00040-6
Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, Abdool R, Hankins CA (2010) HIV and risk environment for injecting drug users: the past, present, and future. Lancet. https://doi.org/10.1016/S0140-6736(10)60743-X
Thomas DL, Vlahov D, Solomon L, Cohn S, Taylor E, Garfein R, Nelson KE (1995) Correlates of hepatitis C virus infections among injection drug users. Medicine (United States). https://doi.org/10.1097/00005792-199507000-00005
Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J, Monterroso ER, Garfein RS (2002) Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. https://doi.org/10.1093/aje/155.7.645
Tsoulfas G, Goulis I, Giakoustidis D, Akriviadis E, Agorastou P, Imvrios G, Papanikolaou V (2009) Hepatitis C and liver transplantation. Hippokratia 13(4):211
Türkcan A (1998) Türkiye’de Madde Kullananlar In Profili: Hastane Verilerinin Incelenmesi. Düşünen Adam
Türkiye İstatistik Kurumu (TUIK) (2018) Adrese Dayalı Nüfus Kayıt Sistemi Sonuçları, 2017 (2018) http://www.tuik.gov.tr/PreHaberBultenleri.do?id=27587%0D
Türkı̇ye Uyuşturucu ve Uyuşturucu Bağımlılığı İzleme Merkezi (TUBİM) (2013)
Viral Hepatitis (n.d.) Centers for disease control and prevention
Wandrer F, Han B, Liebig S, Schlue J, Manns MP, Schulze-Osthoff K, Bantel H (2018) Senescence mirrors the extent of liver fibrosis in chronic hepatitis C virus infection. Aliment Pharmacol Ther. https://doi.org/10.1111/apt.14802
Western Europe Population (n.d.) Worldometers. https://www.worldometers.info/world-population/western-europe-population/. Accessed 10 Feb 2019
World Drug Report (2004) New York
World Health Organization (n.d.) Combating hepatitis B and C to reach elimination by 2030. https://www.who.int/hepatitis/publications/hep-elimination-by-2030-brief/en/. Accessed 10 Jan 2019
World Health Organization (2018) Hepatitis C (2018) https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
Yusuf TT, Francis B (2012) Optimal control of vaccination and treatment for an SIR epidemiological model. World J Model Simul 8(3):194–204 http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.571.8340&rep=rep1&type=pdf
Zeremski M, DImova RB, Pillardy J, De Jong YP, Jacobson IM, Talal AH (2016) Fibrosis progression in patients with chronic hepatitis C virus infection. J Infect Dis. https://doi.org/10.1093/infdis/jiw332
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this paper
Cite this paper
Yaylali, E., Ozdemir, B., Lacin, N., Ceyil, S. (2020). Modelling Hepatitis C Infections Among People Who Inject Drugs in Turkey: Is HCV Elimination Possible?. In: Calisir, F., Korhan, O. (eds) Industrial Engineering in the Digital Disruption Era. GJCIE 2019. Lecture Notes in Management and Industrial Engineering. Springer, Cham. https://doi.org/10.1007/978-3-030-42416-9_32
Download citation
DOI: https://doi.org/10.1007/978-3-030-42416-9_32
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-42415-2
Online ISBN: 978-3-030-42416-9
eBook Packages: EngineeringEngineering (R0)